CHMP recommends Zolgensma for the treatment of patients with 5q spinal muscular atrophy . - Novartis
Related news and insights
Genentech/Roche announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi (risdiplam) in infants with symptomatic Type 1 spinal muscular atrophy (SMA).
Genentech, announced new data for Evrysdi (risdiplam) in spinal muscular atrophy (SMA). Presentations included new three-year data from the SUNFISH study which further confirmed the long-term efficacy and safety of Evrysdi in a broad population of people aged 2-25 years with Type 2 or Type 3 SMA.
Novartis announced new data that reinforce the transformational benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA).